A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 366 participants.

Also called NCT02227784

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 366 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02227784
Other papers using this trial's data
  • Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial Atherosclerosis, 2017-06 DOI, PubMed 28412650

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02227784. Randomized; double masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2018-03-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
Acronym
ACCENTUATE
Condition
Hyperlipidemia
Intervention (Drug)
Evacetrapib
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02227784
Content hash
391f920180ed0e05fa7f246ea42fabb8ddebcb5bd0bf7844d8211b432c37fba5